Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

Lancet

Volumn 352, Issue 9138, 1998, Pages 1413-1418

  Cunningham, David ^a,b   Pyrhönen, Seppo ^c   James, Roger D ^d   Punt, Cornelis J A ^e   Hickish, Tamas F ^f   Heikkila, Reino ^g   Johannesen, Tom B ^h   Starkhammar, Hans ⁱ   Topham, Clare A ^j   Awad, Lucile ^k   Jacques, Christian ^k   Herait, Patrice ^k  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^g Dept Anaesthesia/Intensive Care M   (Norway)

^h UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

ⁱ LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^j St Luke's Hospital Guildford   (United Kingdom)

^k SANOFI   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ATROPINE; FLUOROURACIL; IRINOTECAN; LOPERAMIDE; OCTREOTIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; FEMALE; FEVER; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

EID: 0032585232     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)02309-5     Document Type: Article

References (18)

1. 1 Cohen AM, Minsky BD, Schilsky RL. Cancer of the colon. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 5th edn. Philadelphia: Lippincott-Raven, 1997: 1145-97.
2. 2 The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
3. 3 Fages B, Cote C, Gruia G, et al. Tumor response and stabilization rates are worthwhile surrogate endpoints in metastatic colorectal cancer. analysis of data in 455 5FU-resistant patients treated with CPT-11. Proc ASCO 1997; 16: 288a (abstr).
4. 4 Glimelius B, Hoffman RN, Graf W, et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994; 73: 556-62.
5. 5 The Nordic Gastrointestinal Tumor Adjuvant Project. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 904-11.
6. 6 Marsoni S, Hoth D, Simon R, et al. Clinical drug development. An analysis of phase II trials, 1970-1985. Cancer Treat Rep 1987; 71: 7180.
7. 7 Scheithauer W, Rosen H, Kornek GV, et al. Randomized comparison of combination chemotherapy plus supportive care or supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-55.
8. 8 Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96.
9. 9 Pilot HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910-19.
10. 10 Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60.
11. 11 Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128-35.
12. 12 Van Cutsem E, Rougier P, Droz JP, et al. Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU. Proc ASCO 1997; 16: 268a (abstr).
13. 13 Guidelines for the Reporting of Adverse Drug Reactions. Besthesda: Division of Cancer Treatment. National Cancer Institute, 1988.
14. 14 Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
15. 15 Rougier P, Milan C, Lazorthes F, et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg 1995; 82: 1397-400.
16. 16 Kemeny N, Niedzwiecki D, Shurgot B, et al. Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer 1989; 63: 742-47.
17. 17 Earlam S, Glover C, Fordy C, et al. Relation between tumor size, quality of life and survival in patients with colorectal liver metastases. J Clin Oncol 1996; 14: 171-75.
18. 18 Ross P, Webb A, Cunningham D, et al. Chemotherapy for colorectal cancer: relationship between toxicity and quality of life. Ann Oncol 1996; 7: 34 (abstr).